Abbott Laboratories (ABT) Stock Forecast & Price Target

Compare

8,709 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABT Analyst Ratings

Strong Buy

16 Buy

3 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Abbott

Laboratories

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABT Stock 12 Month Forecast

Average Price Target

$145.75

▲(10.25% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is $145.75 with a high forecast of $159.00 and a low forecast of $135.00. The average price target represents a 10.25% change from the last price of $132.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"110":"$110","135":"$135","160":"$160","122.5":"$122.5","147.5":"$147.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":159,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$159.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":145.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$145.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$135.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[110,122.5,135,147.5,160],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.46,133.57846153846154,135.69692307692307,137.81538461538463,139.93384615384616,142.0523076923077,144.17076923076922,146.28923076923078,148.40769230769232,150.52615384615385,152.64461538461538,154.76307692307694,156.88153846153847,{"y":159,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.46,132.55923076923077,133.65846153846155,134.7576923076923,135.8569230769231,136.95615384615385,138.0553846153846,139.1546153846154,140.25384615384615,141.3530769230769,142.4523076923077,143.55153846153846,144.65076923076924,{"y":145.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.46,131.7323076923077,132.0046153846154,132.27692307692308,132.54923076923077,132.82153846153847,133.09384615384616,133.36615384615385,133.63846153846154,133.91076923076923,134.18307692307692,134.45538461538462,134.7276923076923,{"y":135,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":111.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.42,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.76,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.29,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$159.00

Average Price Target$145.75

Lowest Price Target$135.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Adam Maeder

Piper Sandler

$150

Buy

13.46%

Upside

Reiterated

09/05/25

Piper Sandler Remains a Buy on Abbott Laboratories (ABT)

Lila Implantra

TR | OpenAI - 4o

$149

Buy

12.71%

Upside

Reiterated

09/03/25

AI Generated ArticleAI Generated Article

Mike Kratky

Leerink Partners

―

Hold

―

Reiterated

08/29/25

We expect Navitor's CE Mark, expanding the label to low- and intermediate-risk patients with severe AS, to represent a modest incremental positive for ABT (MP). This expanded label could help level the OUS playing field with both EW (MP) and MDT (OP) who previously received CE Mark across all risk categories. As a reminder, EW's SAPIEN 3 received CE Mark in intermediate risk patients in 2016, low risk patients in 2019, and remains the only TAVR valve indicated for asymptomatic severe patients in Europe. FX+ received CE Mark for all risk categories in 2024. Considering the BSX (OP) OUS share newly up-for-grabs following ACURATE's recent discontinuation, we believe the additional eligibility resulting from this label expansion could represent a modest incremental growth driver for ABT's OUS TAVR franchise.

Joanne Wuensch

Citi

$155

Buy

17.25%

Upside

Reiterated

08/27/25

Wall Street Analysts Are Bullish on Top Healthcare PicksWe rate ABT and MDT Buy, and EW Buy/Top Pick with a Positive Catalyst Watch.

Matthew Taylor

Jefferies

―

Buy

―

Reiterated

08/18/25

We reiterate our Buy rating on shares of DXCM, ABT, PODD, and TNDM, with a Hold rating on MDT.

Larry Biegelsen

Wells Fargo

$151→$142

Buy

7.41%

Upside

Reiterated

07/21/25

Analysts' Top Healthcare Picks: Jazz Pharmaceuticals (JAZZ), Abbott Laboratories (ABT)

Danielle Antalffy

UBS

$148

Buy

11.95%

Upside

Reiterated

07/21/25

UBS Remains a Buy on Abbott Laboratories (ABT)UBS analyst Danielle Antalffy reiterated a Buy rating and $148.00 price target on Abbott Labs (NYSE: ABT).

Jayson Bedford

Raymond James

$142→$141

Buy

6.66%

Upside

Reiterated

07/18/25

Abbott price target lowered to $141 from $142 at Raymond JamesAbbott price target lowered to $141 from $142 at Raymond James

Suraj Kalia

Oppenheimer

$140

Buy

5.90%

Upside

Reiterated

07/18/25

Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (NASDAQ: GANX), Abbott Laboratories (NYSE: ABT) and ANI Pharmaceuticals (NASDAQ: ANIP)

Matt Miksic

Barclays

$159

Buy

20.27%

Upside

Reiterated

07/18/25

Analysts Offer Insights on Healthcare Companies: Elevance Health (NYSE: ELV), Tarsus Pharmaceuticals (NASDAQ: TARS) and Abbott Laboratories (NYSE: ABT)

Travis Steed

Bank of America Securities

$150

Buy

13.46%

Upside

Reiterated

07/18/25

Buy Rating on Abbott Laboratories: Attractive Valuation Amid Growth Prospects and Market Overreaction

Anthony Petrone

Mizuho Securities

$140→$135

Hold

2.12%

Upside

Reiterated

07/18/25

Mizuho Securities Remains a Hold on Abbott Laboratories (ABT)

Rick Wise

Stifel Nicolaus

$145

Buy

9.68%

Upside

Reiterated

07/18/25

Stifel Nicolaus Keeps Their Buy Rating on Abbott Laboratories (ABT)

David Roman

Goldman Sachs

$153

Buy

15.73%

Upside

Reiterated

07/17/25

Goldman Sachs Sticks to Their Buy Rating for Abbott Laboratories (ABT)

Josh Jennings

TD Cowen

$145

Buy

9.68%

Upside

Reiterated

07/17/25

Abbott Laboratories: Strong Medical Devices Performance and Resilient Growth Amid Challenges

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Adam Maeder

Piper Sandler

$150

Buy

13.46%

Upside

Reiterated

09/05/25

Piper Sandler Remains a Buy on Abbott Laboratories (ABT)

Lila Implantra

TR | OpenAI - 4o

$149

Buy

12.71%

Upside

Reiterated

09/03/25

AI Generated ArticleAI Generated Article

Mike Kratky

Leerink Partners

―

Hold

―

Reiterated

08/29/25

Joanne Wuensch

Citi

$155

Buy

17.25%

Upside

Reiterated

08/27/25

Wall Street Analysts Are Bullish on Top Healthcare PicksWe rate ABT and MDT Buy, and EW Buy/Top Pick with a Positive Catalyst Watch.

Matthew Taylor

Jefferies

―

Buy

―

Reiterated

08/18/25

We reiterate our Buy rating on shares of DXCM, ABT, PODD, and TNDM, with a Hold rating on MDT.

Larry Biegelsen

Wells Fargo

$151→$142

Buy

7.41%

Upside

Reiterated

07/21/25

Analysts' Top Healthcare Picks: Jazz Pharmaceuticals (JAZZ), Abbott Laboratories (ABT)

Danielle Antalffy

UBS

$148

Buy

11.95%

Upside

Reiterated

07/21/25

UBS Remains a Buy on Abbott Laboratories (ABT)UBS analyst Danielle Antalffy reiterated a Buy rating and $148.00 price target on Abbott Labs (NYSE: ABT).

Jayson Bedford

Raymond James

$142→$141

Buy

6.66%

Upside

Reiterated

07/18/25

Abbott price target lowered to $141 from $142 at Raymond JamesAbbott price target lowered to $141 from $142 at Raymond James

Suraj Kalia

Oppenheimer

$140

Buy

5.90%

Upside

Reiterated

07/18/25

Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (NASDAQ: GANX), Abbott Laboratories (NYSE: ABT) and ANI Pharmaceuticals (NASDAQ: ANIP)

Matt Miksic

Barclays

$159

Buy

20.27%

Upside

Reiterated

07/18/25

Analysts Offer Insights on Healthcare Companies: Elevance Health (NYSE: ELV), Tarsus Pharmaceuticals (NASDAQ: TARS) and Abbott Laboratories (NYSE: ABT)

Travis Steed

Bank of America Securities

$150

Buy

13.46%

Upside

Reiterated

07/18/25

Buy Rating on Abbott Laboratories: Attractive Valuation Amid Growth Prospects and Market Overreaction

Anthony Petrone

Mizuho Securities

$140→$135

Hold

2.12%

Upside

Reiterated

07/18/25

Mizuho Securities Remains a Hold on Abbott Laboratories (ABT)

Rick Wise

Stifel Nicolaus

$145

Buy

9.68%

Upside

Reiterated

07/18/25

Stifel Nicolaus Keeps Their Buy Rating on Abbott Laboratories (ABT)

David Roman

Goldman Sachs

$153

Buy

15.73%

Upside

Reiterated

07/17/25

Goldman Sachs Sticks to Their Buy Rating for Abbott Laboratories (ABT)

Josh Jennings

TD Cowen

$145

Buy

9.68%

Upside

Reiterated

07/17/25

Abbott Laboratories: Strong Medical Devices Performance and Resilient Growth Amid Challenges

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abbott Laboratories

1 Month

xxx

Success Rate

20/28 ratings generated profit

Average Return

+1.16%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +1.16% per trade.

3 Months

xxx

Success Rate

22/28 ratings generated profit

Average Return

+5.19%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 78.57% of your transactions generating a profit, with an average return of +5.19% per trade.

1 Year

Rick WiseStifel Nicolaus

Success Rate

24/25 ratings generated profit

Average Return

+16.24%

reiterated a buy rating 2 months ago

Copying Rick Wise's trades and holding each position for 1 Year would result in 96.00% of your transactions generating a profit, with an average return of +16.24% per trade.

2 Years

xxx

Success Rate

20/24 ratings generated profit

Average Return

+16.61%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +16.61% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABT Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABT has received 35 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. ABT average Analyst price target in the past 3 months is 145.75.

Each month's total comprises the sum of three months' worth of ratings.

ABT Financial Forecast

ABT Earnings Forecast

Next quarter’s earnings estimate for ABT is $1.30 with a range of $1.28 to $1.37. The previous quarter’s EPS was $1.26. ABT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.08% of the time in the same period. In the last calendar year ABT has Outperformed its overall industry.

ABT Sales Forecast

Next quarter’s sales forecast for ABT is $11.40B with a range of $11.17B to $11.50B. The previous quarter’s sales results were $11.14B. ABT beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.27% of the time in the same period. In the last calendar year ABT has Outperformed its overall industry.

ABT Stock Forecast FAQ

What is ABT’s average 12-month price target, according to analysts?

Based on analyst ratings, Abbott Laboratories’s 12-month average price target is 145.75.

What is ABT’s upside potential, based on the analysts’ average price target?

Abbott Laboratories has 10.25% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ABT a Buy, Sell or Hold?

Abbott Laboratories has a consensus rating of Strong Buy which is based on 16 buy ratings, 3 hold ratings and 0 sell ratings.

What is Abbott Laboratories’s price target?

The average price target for Abbott Laboratories is 145.75. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $159.00 ,the lowest forecast is $135.00. The average price target represents 10.25% Increase from the current price of $132.2.

What do analysts say about Abbott Laboratories?

Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of ABT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Abbott Laboratories (ABT) Stock Forecast & Price Target

ABT Analyst Ratings

ABT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Abbott Laboratories

ABT Analyst Recommendation Trends

ABT Financial Forecast

ABT Earnings Forecast

ABT Sales Forecast

ABT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts